Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278106 · ClinicalTrials.gov registry record · Phase 2
TAS-102 in Treating Advanced Biliary Tract Cancers
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03278106: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03278106 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03278106, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2021-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03278106
The ClinicalTrials.gov registry entry for NCT03278106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03278106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03278106 about?
NCT03278106 is a clinical study titled "TAS-102 in Treating Advanced Biliary Tract Cancers". This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combinati...
What is the current status of trial NCT03278106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2017-10-20. Estimated completion is 2021-09-16.
What interventions are being tested in trial NCT03278106?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 (DRUG).
Who is sponsoring clinical trial NCT03278106?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.